Neurogene (NGNE) | Stock Overview & Key Data

Neurogene Inc. | Healthcare

$20.56

15.83%

| Neurogene Stock Comparison:

Neurogene vs Vertex Neurogene vs Regeneron Neurogene vs Cg Oncology Neurogene vs Denali Therapeutics Neurogene vs Ligand Neurogene vs S&P 500 | Market

Chart Range Statistics Financials Returns Ownership Calculator FAQ

Neurogene Performance Comparison

Loading chart data...

Neurogene

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $17.70 High: $20.78

on June 3, 2025

52 Week Range

Low: $6.88 High: $74.49

on April 8, 2025

on November 11, 2024

All-Time High: $1,115.00 on August 10, 2015

Key Statistics

Market Cap i $267.3M

EPS i -4.36

P/E Ratio (TTM) i N/A

Forward P/E i -4.04

P/B Ratio i 0.96

PEG Ratio i -4.04

Div. Yield i 0.00%

ROE i -34.97%

Beta i N/A

Debt to Equity i 4.01

Financial Highlights

Profitability

Gross Margin i N/A

Operating Margin i -9,701.19%

Profit Margin i 0.00%

Returns and Earnings

Return on Assets (TTM) i -21.97%

Return on Equity (TTM) i -34.97%

EBITDA i $-86.6M

Net Income (TTM) i $-80.9M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i N/A

Quarterly Earnings Growth i N/A

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Neurogene NGNE	267.27M Small-cap	20.30%	36.07%	26.84%	-7.97%	-10.18%	-52.67%	-11.24%	-93.00%
Vertex VRTX	114.81B Large-cap	0.11%	-10.74%	-7.62%	-2.30%	10.04%	-7.56%	75.18%	66.26%
Regeneron REGN	65.36B Large-cap	-19.13%	-19.17%	-28.77%	-34.91%	-31.79%	-51.37%	-14.70%	-17.11%
Cg Oncology CGON	2.00B Small-cap	4.98%	-4.93%	6.73%	-23.24%	-7.53%	-23.24%	-23.52%	-23.52%
Denali Therapeutics DNLI	1.97B Small-cap	5.45%	-12.88%	-8.36%	-41.69%	-33.16%	-32.88%	-38.26%	-43.59%
Ligand LGND	1.95B Small-cap	0.70%	-3.76%	-8.76%	-14.66%	-5.60%	25.59%	106.59%	50.04%

Ownership & Short Interest

Insider Ownership i 9.28%

Institutional Ownership i 116.03%

Shares Short i 3M

Short Ratio i 11.21

Short % of Shares Outstanding i 23.99%

Average 10-Day Volume i 204K

Average 90-Day Volume i 222K

Neurogene Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Neurogene would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is NGNE's 52-week high and low?

In the last 52 weeks, Neurogene reached a high of $74.49 (on November 11, 2024) and a low of $6.88 (on April 8, 2025).

What is the market cap and P/E ratio for NGNE?

Curious about Neurogene's size and valuation? Its market capitalization stands at 267.27M. When it comes to valuation, the P/E ratio (trailing twelve months) is N/A, and the forward P/E (looking ahead) is -4.04.

Does NGNE pay dividends? If so, what's the yield?

As for dividends, Neurogene isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Neurogene's main competitors or similar companies to consider before investing?

When looking at Neurogene, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Vertex VRTX	114.81B	Healthcare	Biotechnology	-7.56%	75.18%
Regeneron REGN	65.36B	Healthcare	Biotechnology	-51.37%	-14.70%
Cg Oncology CGON	2.00B	Healthcare	Biotechnology	-23.24%	-23.52%
Denali Therapeutics DNLI	1.97B	Healthcare	Biotechnology	-32.88%	-38.26%
Ligand LGND	1.95B	Healthcare	Biotechnology	25.59%	106.59%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Neurogene Inc.? (e.g., ROE, Debt/Equity)

To get a sense of Neurogene's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -34.97%, the Debt to Equity ratio from the most recent quarter is 4.01, and its Gross Profit Margin stands at N/A.

What is the recent revenue and earnings growth for NGNE?

Looking at Neurogene's growth, its revenue over the trailing twelve months (TTM) was $925K. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of N/A.

How much of NGNE stock is held by insiders and institutions?

Wondering who owns Neurogene stock? Company insiders (like executives and directors) hold about 9.28% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 116.03%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.